Navigation Links
Novagali Pharma Announces Positive Vekacia Clinical Results From,Pivotal Phase III Trial in Vernal Keratoconjunctivitis

EVRY, France, April 04, 2007 /PRNewswire/ -- Novagali Pharma, an emerging ophthalmic pharmaceutical company specialized in ophthalmology, announces today positive results from the Phase III clinical study of Vekacia(R) in children suffering from Vernal Keratoconjunctivitis (VKC). In this orphan disease, it was shown that both symptoms and signs of disease improved in patients receiving Vekacia(R). Furthermore, the tolerability to Vekacia(R) was excellent.

VKC is a severe form of chronic allergic conjunctivitis characterized by ocular discomfort, pain, itching and intense photophobia, which severely debilitates the patients. This rare disease affects mostly children and young adults living in warm climates worldwide. In March 2006, Novagali received European Medicines Agency (EMEA) orphan drug designation for Vekacia(R) in the treatment of VKC.

The study was conducted by key experts and opinion leaders in the field of ocular allergy throughout Europe and Mediterranean area and lead by Pr David Ben Ezra, Hadassah Hebrew University Hospital, Jerusalem, who first reported on the use and potential efficacy of Cyclosporine A for the treatment of VKC.

Vekacia(R) is a topical Cyclosporine A cationic emulsion enabling an efficient and unmatched-level drug absorption in tissues of the eye leading to optimal therapeutic efficacy. This proprietary ophthalmic emulsion of Cyclosporine A will be the first therapeutic product dedicated to treatment of such a severe ocular condition.

"We achieved a major corporate milestone completing our first phase III clinical trial" declares Jerome Martinez, President & CEO of Novagali, "I am very enthusiastic about the confirmation of the high potential of Novasorb(R) cationic emulsion technology through the development of Vekacia(R) and its successful use in VKC. It is very encouraging for the other ongoing projects".

"It is a great satisfaction to b
'"/>




Page: 1 2

Related medicine technology :

1. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
(Date:1/14/2014)...   Oligomerix, Inc. , a privately held company pioneering ... (AD) and related neurodegenerative disorders, announced today the relocation ... as of January 15, 2014 and expanded ... Medical College. Oligomerix, which is focused on ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Inc. (OTCBB: ECTE), a company developing its needle-free ... continuous glucose monitoring system and its Prelude™ SkinPrep ... Patrick T. Mooney, M.D., CEO, President and Chairman ... at the Jefferies 2011 Global Healthcare Conference. ...
... CHENGDU, China, June 3, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical ... pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized ... announced that the Board of Directors has reinstated the ... to 3 million TPI,s common stock on the open ...
Cached Medicine Technology:TPI Board Reinstates Stock Repurchase Program 2
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
(Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival ... cancer of the abdomen when treated with cytoreductive ... to a first-of-its-size analysis by physicians at Wake ... has the largest reported, single-center experience with cytoreductive ... Levine, M.D., and analysis of 20 years, worth ...
(Date:4/17/2014)... 2014 Giving patients adrenaline after they suffer a cardiac ... prospects of surviving long-term, according to new research conducted ... patients who have a cardiac arrest get adrenaline, which ... for decades," said Dr. Steve Lin, an emergency physician ... advances in medical treatment, long-term survival rates of patients ...
(Date:4/16/2014)... The Translational Genomics Research Institute (TGen) recently honored two ... their support of TGen,s research into brain, colon and ... Scottsdale. , Catherine Ivy, Founder and President of The ... McCain Leadership Award, named for U.S. Sen. John McCain ...
Breaking Medicine News(10 mins):Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... Drug Information Association (DIA), in collaboration with FDA, the Medical ... Radiopharmaceuticals (CORAR), PhRMA, and the American Medical Informatics Association (AMIA), ... Uses of Medical Imaging in the Development of New Biopharmaceutical ... ...
... is a break-through Nitinol wire product which features an exclusive ... acid solutions which cause embrittlement. The resulting NitiBrite™ ... other known methods. , ... West ...
... Komen for the Cure(R), the,leader of the global ... G. Komen for the Cure Advocacy Alliance, have ... self awareness and the need for,increased access to ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO ), Komen for the ...
... Companies Will Discuss Recent FDA Advisory Regarding Byetta, ... LLY ) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... 2008 at 5:00 p.m. EDT to discuss the,recent FDA ... Lilly will be Donald Therasse, M.D., vice president of ...
... fail to alert docs to effectiveness of alternative therapies ... slowed the use of antipsychotic drugs in seniors with ... the elderly increased, a finding which suggests that warnings ... say. , Between late 2002 and June 2005, ...
... HCA marked its 40th,anniversary during a special program for ... featured HCA Co-Founder and Chairman Emeritus, Dr. Thomas,Frist, Jr. ... who spoke about,HCA,s founding, mission and tradition of caring ... of Caring" program was a,prelude to HCA,s annual Caring ...
Cached Medicine News:Health News:Shaping Best Practices For Standardized Medical Imaging In Clinical Trials 2Health News:Shaping Best Practices For Standardized Medical Imaging In Clinical Trials 3Health News:NitiBrite™ - Break-through in Nitinol Wire Product for Medical Devices 2Health News:Komen Travels to Democratic Convention in Denver to Raise Awareness of Breast Cancer Issues 2Health News:Lilly and Amylin Set Date and Time for Conference Call 2Health News:Antipsychotic Drug Use Up in Elderly Despite Warnings 2Health News:HCA Celebrates 40th Anniversary 2
... To Manually Dilate A Small Pupil With ... Maximizes Safety By Allowing The Iris Hooks ... To The Plane Of The Anterior Capsule, ... Tears. Pupil Stretching Is Also Maximized, With ...
... To Rest Either Nasally Or Temporally ... Allowing Eyelids To Be Opened From ... Possible Aperture., ,Open And Close With ... To The Globe During Clear Corneal ...
... Designed To Rest Either Nasally Or ... Over, Allowing Eyelids To Be Opened ... Widest Possible Aperture.,Open And Close With ... To The Globe During Clear Corneal ...
... Special Low-profile Hourglass Jaw Design Holds ... A Minimal Incision.,Mirror Polished Blades Keep ... Handle Mechanism Offers Control Over Release ... The Lens From Tilting During Insertion.,Reusable, ...
Medicine Products: